Drug Approval | August 31, 2025
FDA suspends Valneva’s license of chikungunya vaccine IXCHIQ in US
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
The sudden subsequent decision to suspend IXCHIQ is based on updated VAERS data
Triggering global regulatory submissions this year for the treatment of obesity
Collaboration reinforces Boehringer Ingelheim’s expertise in microbial contract development and manufacturing
The safety profile in alopecia areata was generally consistent with that in approved indications, and no new safety signals were identified in this study
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
FDA requests Sarepta Therapeutics to suspend distribution of Elevidys and places clinical trials on hold for multiple gene therapy products following 3 deaths
Subscribe To Our Newsletter & Stay Updated
